Request Demo
Recent blog posts
Latest Hotspot
8 min read
Wilson disease with hepatic presentation Indication Strategy Report 2026: ATP7B, Trials and Deals
3 August 2026
2026 Wilson disease with hepatic presentation indication strategy covering epidemiology, ATP7B biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Gilbert syndrome Indication Strategy Report 2026: UGT1A1, Trials and Deals
3 August 2026
2026 Gilbert syndrome indication strategy covering epidemiology, UGT1A1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Rotor syndrome Indication Strategy Report 2026: SLCO1B1, Trials and Deals
3 August 2026
2026 Rotor syndrome indication strategy covering epidemiology, SLCO1B1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Dubin-Johnson syndrome Indication Strategy Report 2026: ABCC2, Trials and Deals
3 August 2026
2026 Dubin-Johnson syndrome indication strategy covering epidemiology, ABCC2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Benign recurrent intrahepatic cholestasis Indication Strategy Report 2026: ATP8B1, Trials and Deals
3 August 2026
2026 Benign recurrent intrahepatic cholestasis indication strategy covering epidemiology, ATP8B1 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Choledochal cyst Indication Strategy Report 2026: TGF-beta, Trials and Deals
3 August 2026
2026 Choledochal cyst indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Biliary atresia Indication Strategy Report 2026: TGF-beta, Trials and Deals
3 August 2026
2026 Biliary atresia indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Alagille syndrome Indication Strategy Report 2026: NOTCH2, Trials and Deals
3 August 2026
2026 Alagille syndrome indication strategy covering epidemiology, NOTCH2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Caroli disease Indication Strategy Report 2026: PKD1, Trials and Deals
3 August 2026
2026 Caroli disease indication strategy covering epidemiology, PKD1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Small-duct primary sclerosing cholangitis Indication Strategy Report 2026: FXR, Trials and Deals
3 August 2026
2026 Small-duct primary sclerosing cholangitis indication strategy covering epidemiology, FXR biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Occult hepatitis B infection Indication Strategy Report 2026: HBV polymerase, Trials and Deals
3 August 2026
2026 Occult hepatitis B infection indication strategy covering epidemiology, HBV polymerase biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Autoimmune hepatitis type 1 Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Autoimmune hepatitis type 1 indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market…